Appili Therapeutics Profit Margin

The latest profit margin for APLIF is -1236.07% as of June 2026. That compares with -2279.26% in the prior-year period — up 45.8% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Appili Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, APLIF's profit margin moved from -2279.26% to -1236.07% — a 45.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Appili Therapeutics's valuation or profitability profile.

Against Healthcare companies, APLIF currently prints -1236.07% for profit margin, while the sector average sits near 10.58%. That is roughly 11782.6% below the sector mean. Large gaps often invite a closer look at Appili Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Appili Therapeutics converts resources into returns. At -1236.07%, APLIF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2279.26% in the prior-year period — up 45.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting APLIF's profit margin (-1236.07%), review year-over-year change from -2279.26%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.